Context
The United States, under President Donald Trump, invoked Section 232 of the Trade Expansion Act to impose a 100% ad valorem tariff on imported patented drugs and Active Pharmaceutical Ingredients (APIs). The U.S. administration cited national security concerns
arising from excessive dependence on foreign pharmaceutical supply chains.
Why has the U.S. imposed the tariff?
The U.S. government highlighted that nearly:
- 53% of patented drugs consumed in the U.S. are imported.
- 85% of APIs are sourced from foreign countries.
This dependence is viewed as a strategic vulnerability, especially during geopolitical tensions or global health emergencies. Therefore, the tariff seeks to encourage domestic pharmaceutical manufacturing and reduce supply-chain risks.
Key Features of the Tariff Policy
- Compliance Timeline
- Large pharmaceutical firms have 120 days (till July 31, 2026).
- Smaller firms have 180 days to enter compliance agreements.
- Pricing Safe-Harbour
Companies can avoid tariffs till 2029 if they:
- Adopt Most Favoured Nation (MFN) pricing mechanisms.
- Commit to shifting manufacturing to the U.S.
- Exemptions
The U.S. excluded:
- Generic medicines
- Biosimilars
- Orphan drugs
- Cell and gene therapies
These exemptions aim to prevent shortages of affordable and specialised medicines.
Impact on India
India is one of the largest exporters of pharmaceuticals to the U.S. However, the immediate impact is expected to remain limited because:
- Around 90% of India’s exports to the U.S. are generic medicines, which are exempt from tariffs.
- India mainly supplies low-cost medicines rather than patented drugs.
Nevertheless, the move reflects growing protectionism in global trade and could indirectly affect Indian pharmaceutical companies in the future.
Concerns Associated with the Move
Economic Concerns
- Higher tariffs may increase medicine prices in the U.S.
- Pharmaceutical supply chains could become more fragmented.
Trade Concerns
- The move may trigger retaliatory trade measures.
- It reflects increasing use of “national security” exceptions in trade policy.
Global Health Concerns
- Reduced global cooperation in pharmaceuticals may affect affordability and accessibility of medicines.
Significance for India
The development highlights the need for India to:
- Strengthen domestic API manufacturing.
- Reduce dependence on Chinese imports.
- Expand pharmaceutical innovation and R&D.
Government initiatives such as the Production Linked Incentive (PLI) Scheme for bulk drugs can help India emerge as a stronger pharmaceutical manufacturing hub.
Conclusion
The U.S. tariff on patented drugs and APIs marks a shift towards strategic economic nationalism in critical sectors such as healthcare. While India remains relatively insulated due to the exemption for generic medicines, the policy underlines the importance of resilient supply chains and self-reliance in pharmaceuticals.